Overexpression of LAPTM4B: An independent prognostic marker in breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 4, 2013, Pages 661-667

  Xiao, Min ^a   Jia, Shusheng ^a   Wang, Hongbin ^a   Wang, Jinsong ^a   Huang, Yuanxi ^a   Li, Zhigao ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Immunohistochemistry; LAPTM4B; Prognosis

Indexed keywords

LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4 BETA; ONCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN BREAST TUMOR; BREAST CARCINOMA; BREAST TUMOR; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONCOGENE PROTEINS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876414664     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1368-y     Document Type: Article

References (20)

1. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373(9673):1463-1479
2. Fan M, Liu Y, Zhou R, Zhang Q (2012) Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol. Epub ahead of print
3. Joensuu H, Pylkkänen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198
4. Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B (2005) The human LAPTM4B transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224:93-103
5. Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ, Zhou RL (2010a) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29:5785-5795
6. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC (2010b) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16:214-218
7. Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, Rui JA, Ye DX (2004) Structure analysis and expressions of a novel tetratransmembrane protein, lysosome associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol 10:1555-1559
8. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipides T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa CD, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G (2006) Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 17:1504-1511
9. Martinez-Arribas F, Alvarez T, Del Val G, Martin-Garabato E, Nunez-Villar MJ, Lucas R, Sanchez J, Tejerina A, Schneider J (2007) Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 27:219-222
10. Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, Zhou R (2010a) LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol 29(6):587-593. Erratum in: Int J Gynecol Pathol 2011;30(3):314-315
11. Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL (2010b) LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 20(5):745-750
12. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32
13. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4):307-325
14. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22:5060-5069
15. Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, Zhou R (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20(5):1077-1083
16. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL (2010) LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 136(2):275-281
17. Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R (2011) Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol 104(1):29-36
18. Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X, Zhou R, Dong X, Lou G (2012) LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer 22(1):54-62
19. Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL, Rui JA, Yu JC (2008) Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 264(2):209-217
20. Zhou L, He XD, Yu JC, Zhou RL, Shan Y, Rui JA (2011) Overexpression of LAPTM4B-35 attenuates epirubicin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery 150(1):25-31